I'll verify Mylan's profile with a couple of searches.
Mylan N.V. (commonly "Mylan") was a generic and specialty pharmaceutical company founded in 1961 in Morgantown, West Virginia by Milan Puskar and Don Panoz, and later run from a global operations center at 1000 Mylan Blvd., Canonsburg, Pennsylvania. It was publicly traded on Nasdaq under the ticker MYL, and reincorporated in the Netherlands in 2015 as Mylan N.V. Pre-merger it reported roughly $11–12 billion in annual revenue with about 35,000 employees.
Products / operations. Mylan was an operating company, not an NPE. It developed, manufactured, and sold generic and branded medicines — oral solid doses, injectables, complex generics, active pharmaceutical ingredients, biosimilars, and over-the-counter products — across cardiovascular, CNS, oncology, respiratory, diabetes, infectious disease, and women's health areas. Its best-known branded products were the EpiPen auto-injector and the Mylan-branded generics portfolio. In November 2020 it combined with Pfizer's Upjohn business to form Viatris Inc. (Nasdaq: VTRS); Mylan Inc. is now a wholly owned indirect subsidiary of Viatris, and the Mylan name is no longer a standalone corporate entity.
Patent-litigation posture. Both tracked cases — Celgene Corp. v. Mylan (District of New Jersey, listed twice) — show Mylan as defendant and never as plaintiff, consistent with an operating generic manufacturer defending Hatch-Waxman/ANDA patent suits brought by brand holders. The venue is the District of New Jersey, the home district for both parties, not a plaintiff-friendly outlier such as the Eastern District of Texas.
Notable cases / context. The tracked Celgene v. Mylan matters reflect the long-running Revlimid/lenalidomide and Thalomid/thalidomide disputes, in which Celgene asserted method-of-use and polymorph patents against Mylan's ANDA filings. That litigation was broader than the patent suits alone: Mylan separately pursued antitrust claims against Celgene in the District of New Jersey, and the Revlimid generics settlements subsequently became the subject of multi-district purchaser antitrust litigation. Post-merger, Viatris continues to defend the inherited Mylan product portfolio in patent litigation.